Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Helman Website

Lee J. Helman, M.D.

Selected Publications

1)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. [Epub ahead of print], 2013.
[Journal]
2)  Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jahromi MS, Xekouki P, Szarek E, Walker R, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu YJ, Wang Y, Waterfall J, O'Sullivan M, Bibikova M, Pacak K, Stratakis CA, Janeway KA, Schiffman JD, Fan J, Helman LJ, Meltzer PS.
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
Cancer Discov. [Epub ahead of print], 2013.
[Journal]
3)  Grohar PJ, Helman LJ.
Prospects and challenges for the development of new therapies for Ewing sarcoma.
Pharmacol. Ther. 137: 216-24, 2013.
[Journal]
4)  Wiener L, Battles H, Zadeh S, Smith CJ, Helman LJ, Kim SY.
Gastrointestinal stromal tumor: psychosocial characteristics and considerations.
Support Care Cancer. 20: 1343-9, 2012.
[Journal]
5)  Schayek H, Bentov I, Jacob-Hirsch J, Yeung C, Khanna C, Helman LJ, Plymate SR, Werner H.
Global Methylation Analysis Identifies PITX2 as an Upstream Regulator of the Androgen Receptor and IGF-I Receptor Genes in Prostate Cancer.
Horm. Metab. Res. 44: 511-9, 2012.
[Journal]
6)  Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, Staudt LM, Helman LJ.
Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma.
Cancer Res. 72: 5889-99, 2012.
[Journal]
7)  Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ.
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Oncologist. 17: 321, 2012.
[Journal]
8)  Teicher BA, Linehan WM, Helman LJ.
Targeting cancer metabolism.
Clin. Cancer Res. 18: 5537-45, 2012.
[Journal]
9)  Arnaldez FI, Helman LJ.
Targeting the insulin growth factor receptor 1.
Hematol. Oncol. Clin. North Am. 26: 527-42, vii-viii, 2012.
[Journal]
10)  Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.
The first European interdisciplinary ewing sarcoma research summit.
Front Oncol. 2: 54, 2012.
[Journal]
11)  Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Neoplasia. 13: 145-53, 2011.
[Journal]
12)  Meltzer PS, Helman LJ.
Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome.
Cancer Discov. 1: 555-6, 2011.
[Journal]
13)  Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen Q, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.
Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening.
J Natl Cancer Inst. [Epub ahead of print], 2011.
[Journal]
14)  Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
J. Clin. Oncol. 29: 4541-7, 2011.
[Journal]
15)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
[Journal]
16)  Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.
Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Cancer Res. 70: 6497-508, 2010.
[Journal]
17)  Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L.
Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).
Oncogene. 29: 6367-77, 2010.
[Journal]
18)  Kim SY, Helman LJ.
Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma.
Cancer Treat Res. 152: 517-528, 2010.
[Journal]
19)  Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li W, Tuan RS, Deyrup AT, Khanna C, Helman L.
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin.
Oncogene. Epub ahead of print, 2009.
[Journal]
20)  Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Clin. Invest. 119: 3395-407, 2009.
[Journal]
21)  Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C.
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.
Int. J. Cancer. 124: 2042-9, 2009.
[Journal]
22)  Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
J. Clin. Oncol. 27: 2705-11, 2009.
[Journal]
23)  Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Clin. Cancer Res. 15: 7361-7, 2009.
[Journal]
24)  Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE.
Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma.
Pediatr Blood Cancer. 53: 496-8, 2009.
[Journal]
25)  Kim SY, Wan X, Helman LJ.
Targeting IGF-1R in the treatment of sarcomas: past, present and future.
Bull Cancer. 96: E52-60, 2009.
[Journal]
26)  Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM.
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Cancer Res. 69: 161-70, 2009.
[Journal]
27)  Kim SY, Toretsky JA, Scher D, Helman LJ.
The role of IGF-1R in pediatric malignancies.
Oncologist. 14: 83-91, 2009.
[Journal]
28)  Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ.
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
Clin. Cancer Res. 14: 4850-8, 2008.
[Journal]
29)  Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ.
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cancer Res. 68: 8039-48, 2008.
[Journal]
30)  Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Designing phase 0 cancer clinical trials.
Clin. Cancer Res. 14: 3675-82, 2008.
[Journal]
31)  Kim SY, Tsokos M, Helman LJ.
Dilemmas associated with congenital ewing sarcoma family tumors.
J. Pediatr. Hematol. Oncol. 30: 4-7, 2008.
[Journal]
32)  Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY.
Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.
J. Pediatr. Hematol. Oncol. 30: 612-7, 2008.
[Journal]
33)  Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ.
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
Clin. Exp. Metastasis. 25: 201-11, 2008.
[Journal]
34)  Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH.
Osteosarcoma: the same old drugs or more?.
J. Clin. Oncol. 26: 3102-3; author reply 3104-5, 2008.
[Journal]
35)  Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials: conceptions and misconceptions.
Cancer J. 14: 133-7, 2008.
[Journal]
36)  Wayne AS, Reaman GH, Helman LJ.
Progress in the Curative Treatment of Childhood Hematologic Malignancies.
J. Natl. Cancer Inst. 2008.
[Journal]
37)  Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Compressing drug development timelines in oncology using phase '0' trials.
Nat. Rev. Cancer. 7: 131-9, 2007.
[Journal]
38)  Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL.
Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Cancer Immunol. Immunother. 56: 1037-46, 2007.
[Journal]
39)  Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Mol. Interv. 7: 325-34, 2007.
[Journal]
40)  Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA.
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.
Cancer Res. 67: 3431-40, 2007.
[Journal]
41)  Wan X, Harkavy B, Shen N, Grohar P, Helman LJ.
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
Oncogene. 26: 1932-40, 2007.
[Journal]
42)  Wan X, Helman LJ.
The biology behind mTOR inhibition in sarcoma.
Oncologist. 12: 1007-18, 2007.
[Journal]
43)  Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C, Weissman AM.
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.
Nat. Med. 13: 1504-9, 2007.
[Journal]
44)  Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS.
Thromboembolic events in children and young adults with pediatric sarcoma.
J. Clin. Oncol. 25: 1519-24, 2007.
[Journal]
45)  Wan X, Shen N, Mendoza A, Khanna C, Helman LJ.
CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1alpha/VEGF Signaling.
Neoplasia. 8: 394-401, 2006.
[Journal]
46)  Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA.
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Cancer Res. 66: 3869-75, 2006.
[Journal]
47)  Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ.
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.
Clin. Exp. Metastasis. 23: 227-36, 2006.
[Journal]
48)  van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA.
Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
Cancer Res. 66: 1818-23, 2006.
[Journal]
49)  Khanna C, Helman LJ.
Molecular approaches in pediatric oncology.
Annu. Rev. Med. 57: 83-97, 2006.
[Journal]
50)  Krishnan K, Khanna C, Helman L.
The molecular bology of pulmonary metastases, a review.
Thorac Surg Clin. 16: 115-124, 2006.
[Journal]
51)  Mansky P, Helman L.
Abraham J, Allegra C, eds.
Sarcomas and Malignancies of the Bone. In: Bethesda Handbook of Clinical Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2005. p. 265-279 [Book Chapter]
52)  Helman L, Malkin D.
DeVita, Jr. V, Hellman S, Rosenberg S, eds.
Molecular Biology of Childhood Cancers. In: Cancer: Principles and Practice of Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1889-1937 [Book Chapter]
53)  Malawer M, Helman L, O'Sullivan B.
DeVita, Jr. V, Hellman S, Rosenberg S, eds.
Sarcomas of the Bone. In: Cancer: Principles and Practice of Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1638-1686 [Book Chapter]
54)  Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL, Helman LJ.
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience.
Pediatr Blood Cancer. 44: 449-54, 2005.
[Journal]
55)  Capponcelli S, Pedrini E, Cerone MA, Corti V, Fontanesi S, Alessio M, Bachi A, Soddu S, Ribatti D, Picci P, Helman LJ, Cantelli-Forti G, Sangiorgi L.
Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
Hum Mutat. 26: 94-103, 2005.
[Journal]
56)  Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC.
Expression profiles of osteosarcoma that can predict response to chemotherapy.
Cancer Res. 65: 8142-50, 2005.
[Journal]
57)  Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL.
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
Nat. Med. 11: 1238-43, 2005.
[Journal]
58)  Wan X, Mendoza A, Khanna C, Helman LJ.
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
Cancer Res. 65: 2406-11, 2005.
[Journal]
59)  Savage SA, Stewart BJ, Liao JS, Helman LJ, Chanock SJ.
Telomere stability genes are not mutated in osteosarcoma cell lines.
Cancer Genet Cytogenet. 160: 79-81, 2005.
[Journal]
60)  Krishnan K, Khanna C, Helman LJ.
The biology of metastases in pediatric sarcomas.
Cancer J. 11: 306-13, 2005.
[Journal]
61)  Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G.
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.
Nat Med. 10: 175-81, 2004.
[Journal]
62)  Navid F, Mischen BT, Helman LJ.
Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines.
Sarcoma. 8: 25-30, 2004.
[Journal]
63)  Toyoshima Y, Karas M, Yakar S, Dupont J, Lee Helman , LeRoith D.
TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival.
J Biol Chem. 2004.
[Journal]
64)  Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ.
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
Nat Med. 10: 182-6, 2004.
[Journal]
65)  LeRoith D, Helman L.
The new kid on the block(ade) of the IGF-1 receptor.
Cancer Cell. 5: 201-2, 2004.
[Journal]
66)  Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B.
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Clin. Cancer Res. 9: 5442-53, 2003.
[Journal]
67)  Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M.
Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.
Lab Invest. 83: 1255-65, 2003.
[Journal]
68)  Wan X, Helman LJ.
Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells.
Oncogene. 22: 8205-11, 2003.
[Journal]
69)  Helman LJ, Meltzer P.
Mechanisms of sarcoma development.
Nat Rev Cancer. 3: 685-94, 2003.
[Journal]
70)  Helman LJ, Meltzer P.
Mechanisms of sarcoma development.
Nat Rev Cancer. 3: 685-94, 2003.
[Journal]
71)  Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP, Pediatric Oncology Group .
Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
J Clin Oncol. 21: 1574-80, 2003.
[Journal]
72)  Sharp R, Recio J, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman L, DePinho R, Merlino G.
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.
Nat Med. 9: 146, 2003.
[Journal]
73)  Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL.
Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells.
Cancer Biol Ther. 2: 579-86, 2003.
[Journal]
74)  Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ.
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.
Clin Cancer Res. 8: 2406-2412, 2002.
[Journal]
75)  Wan X, Helman LJ.
Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway.
Neoplasia. 4: 400-8, 2002.
[Journal]
76)  Mackall CL, Meltzer PS, Helman LJ.
Focus on sarcomas.
Cancer Cell. 2: 175-8, 2002.
[Journal]
77)  Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL.
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
Med Pediatr Oncol. 38: 158-164, 2002.
[Journal]
78)  Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung C, Helman LJ, Picci P, Carinci P.
Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.
Int J Oncol. 20: 143-147, 2002.
[Journal]
79)  Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, DePinho RA, Merlino G.
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.
Nat Med. 8: 1276-80, 2002.
[Journal]
80)  Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA.
Testing of new agents in childhood cancer preclinical models: meeting summary.
Clin Cancer Res. 8: 3646-57, 2002.
[Journal]
81)  Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ.
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
J Pediatr Hematol Oncol. 24: 440-6, 2002.
[Journal]
82)  Benjamin R, Helman L, Meyers P, Reaman G.
A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Hum. Gene Ther. 12: 1591-3, 2001.
[Journal]
83)  Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA.
Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.
Cancer Res. 61: 6868-6875, 2001.
[Journal]
84)  Mackall CL, Helman LJ.
High-dose chemotherapy for rhabdomyosarcoma: where do we go from here.
J. Pediatr. Hematol. Oncol. 23: 266-7, 2001.
[Journal]
85)  Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, Mackall CL.
Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction.
J Clin Oncol. 19: 3649-3659, 2001.
[Journal]
86)  Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D.
Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis.
Endocrinology. 142: 4969-4975, 2001.
[Journal]
87)  Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D.
Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor.
J Biol Chem. 276: 26699-26707, 2001.
[Journal]
88)  Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, Eskenazi A, Helman L, Wexler LH.
Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors.
Cancer. 92: 2941-2947, 2001.
[Journal]
89)  Weil RJ, Zhuang Z, Pack S, Kumar S, Helman L, Fuller BG, Mackall CL, Oldfield EH.
Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report.
J Neurosurg. 95: 270-275, 2001.
[Journal]
90)  Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L.
Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Cancer Res. 61: 3750-9, 2001.
[Journal]
91)  Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall C, Raffeld M, Tsokos M, Helman L.
Molecular confirmation of Ewing sarcoma.
J Pediatr Hematol Oncol. 23: 221-224, 2001.
[Journal]
92)  Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L.
An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.
Clin Exp Metastasis. 18: 261-271, 2000.
[Journal]
93)  Navid F, Letterio JJ, Yeung CL, Pegtel M, Helman LJ.
Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein.
Sarcoma. 4: 93-102, 2000.
[Journal]
94)  Cope JU, Tsokos M, Helman LJ, Gridley G, Tucker MA.
Inguinal hernia in patients with Ewing sarcoma: a clue to etiology.
Med Pediatr Oncol. 34: 195-9, 2000.
[Journal]
95)  Mackall CL, Helman LJ.
Targeting pediatric malignancies for T cell-mediated immune responses.
Curr Oncol Rep. 2: 539-546, 2000.
[Journal]
96)  Mackall C, Berzofsky J, Helman LJ.
Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy.
Clin. Orthop. Relat. Res. 25-31, 2000.
[Journal]
97)  Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I.
XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma.
Cancer Res. 60: 4752-5, 2000.
[Journal]
98)  Zhang L, Kim M, Choi YH, Goemans B, Yeung C, Hu Z, Zhan S, Seth P, Helman LJ.
Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression.
J Biol Chem. 274: 13118-26, 1999.
[Journal]
99)  Merlino G, Helman LJ.
Rhabdomyosarcoma--working out the pathways.
Oncogene. 18: 5340-8, 1999.
[Journal]
100)  Zhang L, Zhan S, Navid F, Li Q, Choi YH, Kim M, Seth P, Helman LJ.
AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma.
Oncogene. 17: 1261-70, 1998.
[Journal]
101)  Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ.
Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R.
Int J Cancer. 76: 223-7, 1998.
[Journal]
102)  Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ.
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
J Biol Chem. 272: 30822-7, 1997.
[Journal]
103)  Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, Seth P, Helman LJ.
Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis.
Cancer Res. 56: 1367-73, 1996.
[Journal]
104)  Zhan S, Shapiro D, Zhan S, Zhang L, Hirschfeld S, Elassal J, Helman LJ.
Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer.
J Biol Chem. 270: 27983-6, 1995.
[Journal]
105)  Minniti CP, Luan D, O'Grady C, Rosenfeld RG, Oh Y, Helman LJ.
Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype.
Cell Growth Differ. 6: 263-9, 1995.
[Journal]
106)  Zhan S, Shapiro DN, Helman LJ.
Loss of imprinting of IGF2 in Ewing's sarcoma.
Oncogene. 11: 2503-7, 1995.
[Journal]
107)  Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D.
The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis.
J Biol Chem. 270: 29176-81, 1995.
[Journal]
108)  Zhan S, Shapiro DN, Helman LJ.
Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.
J Clin Invest. 94: 445-8, 1994.
[Journal]
109)  Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ.
Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.
Cancer Res. 54: 2803-7, 1994.
[Journal]
110)  Kalebic T, Tsokos M, Helman LJ.
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Cancer Res. 54: 5531-4, 1994.
[Journal]
111)  Minniti CP, Tsokos M, Newton WA, Helman LJ.
Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells.
Am J Clin Pathol. 101: 198-203, 1994.
[Journal]
112)  Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ.
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.
Cancer Res. 52: 2243-7, 1992.
[Journal]
113)  Minniti CP, Maggi M, Helman LJ.
Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
Cancer Res. 52: 1830-5, 1992.
[Journal]
114)  Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Müller HL, Rosenfeld RG, Helman LJ.
The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells.
J Biol Chem. 267: 9000-4, 1992.
[Journal]
115)  El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA.
Insulin-like growth factor II-mediated proliferation of human neuroblastoma.
J Clin Invest. 87: 648-57, 1991.
[Journal]
116)  El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ.
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
Cell Growth Differ. 1: 325-31, 1990.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/11/2013.